Makoto Kubo

Makoto Kubo

Auto-generated profile, based on publicly available information

Makoto Kubo

Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Japan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2018 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
TNTakashi Nawata
Takashi Nawata
MKMakoto Kubo
Makoto Kubo
TNTakafumi Nomura
Takafumi Nomura
KOKeiji Oishi
Keiji Oishi
KSKosaku Shiragami
Kosaku Shiragami
MYMasafumi Yano
Masafumi Yano
Steroid therapy, a key therapy for inflammatory, allergic, and immunological disorders, is often associated with steroid myopathy as one of the side effects. Steroid therapy is considered the first-line therapy for myositis; however, there have been no reports strictly comparing the muscle mass in patients with myositis before and after steroid therapy. Thus, it is currently unclear whether steroid therapy for such patients affects muscle volume in addition to muscle strength. We aimed to determine the change in muscle mass after steroid therapy via cross-sectional computed tomography (CT) in patients with myositis. Data from seven patients with myositis and eight controls, who were all treated with high doses of steroids, were assessed before and after steroid therapy. Clinical factors in patients with myositis included serum muscle enzyme levels and muscular strength. The cross-sectional area of skeletal muscle and the low muscle attenuation rate at the level of the caudal end of the third lumbar vertebra were obtained using CT and measured using an image analysis program for all patients. Data were subjected to statistical analysis using several well-established statistical tests. The Wilcoxon signed-rank test was used for comparing paired data for each patient. The Mann-Whitney U test was used to compare sets of data sampled from two groups. The Spearman’s rank correlation coefficient was used for determining the correlations between two variables. Statistical significance was set at p < 0.05. Muscular strength and serum muscle enzyme levels improved following steroid therapy in patients with myositis. In both groups, the cross-sectional areas of skeletal muscles decreased (myositis group: p = 0.0156; control group: p = 0.0391) and the low muscle attenuation rate tended to increase (myositis group: p = 0.0781; control group: p = 0.0547). In the myositis group, patients with chronic obstructive pulmonary disease showed a tendency toward muscle volume loss (p = 0.0571). In patients with myositis treated with steroid therapy, muscle mass decreased after steroid therapy suggesting that the improvement in muscle strength was due to factors other than a change in muscle volume. Our study suggests the importance of therapies that not only improve muscle mass but also improve the quality of muscle strength.

25 June 2019 in Rheumatology
Verified
Journal Article
Open access
YKYuko Kaneko
Yuko Kaneko
TNTakahiro Nunokawa
Takahiro Nunokawa
YTYoshinori Taniguchi
Yoshinori Taniguchi
YYYukie Yamaguchi
Yukie Yamaguchi
TGTakahisa Gono
Takahisa Gono
YKYoshie Kawahara
Yoshie Kawahara
Objective: To clarify the incidence, risk factors, and impact of malignancy in patients with PM/DM-associated interstitial lung disease (ILD). Methods: This study used data from 497 patients with PM/DM-associated ILD enrolled in a multicentre, retrospective and prospective cohort of incident cases. Cancer-associated myositis (CAM) was defined as malignancy diagnosed within 3 years before or after PM/DM diagnosis. Demographic and clinical information was recorded at the time of diagnosis, and data about the occurrence of mortality and malignancy was collected. Results: CAM was identified in 32 patients with PM/DM-associated ILD (6.4%). Patients with CAM were older (64 vs 55 years, P < 0.001), presented with arthritis less frequently (24% vs 49%, P = 0.01), and showed a lower level of serum Krebs von den Lungen-6 (687 vs 820 IU/l, P = 0.03) than those without CAM. The distribution of myositis-specific autoantibodies, including anti-melanoma differentiation–associated gene 5, anti-aminoacyl tRNA synthetase, and anti-transcriptional intermediary factor 1-γ antibodies, did not differ between the groups. Survival analysis demonstrated that CAM patients had a poorer survival than non-CAM patients (P = 0.006), primarily due to excess deaths by concomitant malignancy, while mortality due to ILD-related respiratory failure was similar between the groups (P = 0.51). Conclusion: Concomitant malignancy can occur in patients with PM/DM-associated ILD, and has significant impact on mortality. Older age, lack of arthritis, and a lower level of serum Krebs von den Lungen-6 at diagnosis are predictors of concomitant malignancy.

14 September 2017 in Case Reports in Rheumatology
Verified
Journal Article
Open access
PDF file
TNTakashi Nawata
Takashi Nawata
MKMakoto Kubo
Makoto Kubo
KSKosaku Shiragami
Kosaku Shiragami
YNYukinori Nakamura
Yukinori Nakamura
MYMasafumi Yano
Masafumi Yano
An estimated 0.9% to 2.4% of patients with systemic lupus erythematosus (SLE) also have hemophagocytic lymphohistiocytosis (HLH). HLH associated with autoimmune diseases is often refractory to corticosteroid treatment; thus, additional immunosuppressive drugs, such as cyclosporine, cyclophosphamide, or tacrolimus, are required. Here, we describe the case of a 44-year-old Japanese woman who developed HLH associated with lupus nephritis. Initially, her HLH was refractory to treatment with a corticosteroid, tacrolimus, and mizoribine. However, alternative treatment with a corticosteroid, mycophenolate mofetil, and tacrolimus improved both her HLH and lupus nephritis. This case suggests the possibility of mycophenolate mofetil as a key drug for treating HLH associated with SLE.

4 May 2021 in Japanese Journal of Radiology
Verified
Journal Article
Open access
PDF file
YKYoshie Kunihiro
Yoshie Kunihiro
NTNobuyuki Tanaka
Nobuyuki Tanaka
RKReo Kawano
Reo Kawano
TMTsuneo Matsumoto
Tsuneo Matsumoto
TKTaiga Kobayashi
Taiga Kobayashi
KIKatsuyoshi Ito
Katsuyoshi Ito
Purpose: The purpose of this study was to compare the high-resolution CT (HRCT) findings of pulmonary infectious and noninfectious complications with extensive ground-glass attenuation (GGA) in immunocompromised patients. Materials and methods: One hundred fifty-two immunocompromised patients with pulmonary complications that showed extensive GGA (> 50% of the whole lung on HRCT) were included in this study. The diagnoses of the 152 patients were as follows: pneumocystis pneumonia (PCP), n = 82; drug-induced pneumonia, n = 38; bacterial pneumonia, n = 9; cytomegalovirus pneumonia, n = 6; idiopathic pneumonia syndrome, n = 6; diffuse alveolar hemorrhage (DAH), n = 4; fungal infection, n = 3; tuberculosis, n = 2 and pulmonary edema, n = 2. Two chest radiologists retrospectively evaluated the CT criteria, which consisted of 12 findings. Results: The nodule (p = 0.015), the bronchovascular bundle (BVB) thickening (p = 0.001), and the interlobular septum (ILS) thickening (p = 0.002) were significantly infrequent in PCP. The ILS thickening was significantly frequent in drug-induced pneumonia (p < 0.001) though it was also frequent in other noninfectious and infectious diseases. The BVB thickening was significantly frequent in bacterial pneumonia (p = 0.005). The nodule was significantly frequent in DAH (p = 0.049). Conclusion: Nodules, BVB thickening, and ILS thickening could be useful HRCT findings for the differential diagnosis of pulmonary complications in immunocompromised patients with extensive GGA.

31 July 2021 in Japanese Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
SHShinya Harada
Shinya Harada
HKHayato Kawada
Hayato Kawada
SMShotaro MAEHANA
Shotaro MAEHANA
HMHidehito Matsui
Hidehito Matsui
MKMakoto Kubo
Makoto Kubo
MKMasato Katagiri
Masato Katagiri
Necrotizing pneumonia caused by Panton-Valentine leukocidin (PVL)-positive community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) has high mortality, and is currently a serious clinical issue. PVL is a two-component toxin consisting of LukS-PV and LukF-PV. PVL was shown to cause necrosis in target cells by forming pores consisting of an octamer comprised of LukS-PV and LukF-PV. However, because of the specificity of PVL toward several target cells and species, the detailed action of PVL remains controversial. Therefore, we focused on necrotizing pneumonia caused by PVL-positive Staphylococcus aureus and clarified the effects of PVL on alveolar macrophages, which play a central role in innate immunity in the alveolar space. We constructed recombinant PVL (rPVL) components and stimulated alveolar macrophages isolated from rabbits, and then evaluated the cytotoxicity and pro-inflammatory cytokine release. Recombinant LukS-PV (rLukS-PV), but not recombinant LukF-PV (rLukF-PV), induced pro-inflammatory cytokine release. Especially, TNF-α release was mediated via the C5a receptor (C5aR) expressed in rabbit alveolar macrophages and rPVL, consisting of rLukS-PV and rLukF-PV, was highly toxic to rabbit alveolar macrophages via the same receptor. Our results, which reveal the action of PVL via C5aR on alveolar macrophages, may be useful for understanding the mechanism of necrotizing pneumonia caused by PVL.

1 January 2018 in Internal Medicine
Verified
Journal Article
Open access
PDF file
TNTakashi Nawata
Takashi Nawata
MKMakoto Kubo
Makoto Kubo
HMHitomi Mitsui
Hitomi Mitsui
KOKeiji Oishi
Keiji Oishi
MOMasatoshi Omoto
Masatoshi Omoto
MYMasafumi Yano
Masafumi Yano
A 58-year-old Japanese woman was diagnosed with anti-signal recognition particle (SRP)-positive dermatomyositis associated with Sjögren's syndrome, rheumatoid arthritis and lung adenocarcinoma. She presented with cutaneous lesions, including ulceration of her right middle finger. Tissue specimens obtained from her right deltoid muscle were positive for CD4+ T-cell infiltration and the sarcolemma showed the upregulation of major histocompatibility complex (MHC) class I antigens. The present case suggests that overlapping autoimmune diseases or complications of malignancy may result in an atypical clinical presentations and histological findings in patients with anti-SRP antibody-positive dermatomyositis.